A Phase 2 Trial of Neoadjuvant Chemoradiation With Pembrolizumab Followed by Pembrolizumab With Lenvatinib in Esophageal/Gastroesophageal Junction Squamous Cell and Adenocarcinomas

Status: Active, no longer recruiting

Phase of Trial: Phase II

Latest Information Update: 30 Aug 2024

Price :

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

Drugs Lenvatinib (Primary) ; Pembrolizumab (Primary) ; Carboplatin; Paclitaxel
Indications Adenocarcinoma; Gastric cancer; Oesophageal cancer; Squamous cell cancer
Focus Therapeutic Use

14 Aug 2023 Status changed from recruiting to active, no longer recruiting.
19 Feb 2023 Planned End Date changed from 31 Dec 2024 to 25 Apr 2027.
19 Feb 2023 Planned primary completion date changed from 31 Dec 2024 to 25 Apr 2027.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com